Market close: NZX continues rise, SkyCity falls on exec departures
The New Zealand sharemarket continued its merry way.
The New Zealand sharemarket continued its merry way.
Original sale fell through last week.
Allegations fly as cannabis firm fund raises.
Zuru's Nick Mowbray and MONDAY haircare's Jaimee Lupton talk about the war of the brands.
Kumar rejected bankers' advice to think small, saying "I'm running out of time"
The New Zealand sharemarket finished an eventful week with a small gain.
Australia-bound passengers may also be hit by cancellations as capacity is cut.
Diverging expectations offer opportunities for the likes of Dan Loeb and Bill Ackman.
Jarden's daily update on the latest market moves and shakes.
While the two growth stocks hogged the limelight, the S&P/NZX 50 Index had a flat day.
Synlait's successful capital raising comes as the company resolves a number of issues.
Quarantine requirements in NZ and Hong Kong put the brakes on leisure travel.
In one case the broken blade showered the aircraft's fuselage with shredded metal.
Acquisitions lead to jump in manager incentive fees.
New recruit has recently been involved in sale of NZ retirement village firm for $1.3b
Jarden's daily update on the latest market moves and shakes.
"I've lost four weeks of my life now in quarantine." - Ross Taylor.
Big Blue equals big gains, with headcount increasing by a third. A snipe with analysts.
Coveted European certification will help elbow past rivals in $200b global market.
The market has calmed since yesterday's excitement.
The New Zealand sharemarket had a wild ride.
"We are waiting to hear back from Labour about the resolution."
Improved forecast driven by better than expected revenue recovery from Covid crisis.
Staff say it's another kick while airline says execs crucial in navigating through Covid
Jarden's daily update on the latest market moves and shakes.
The S&P 500 reached record levels off the back of the vaccine news.
Fonterra shareholders' guardian says blurred role helped sour relationship with farmers.
Regulator concern at 'incomplete' framework for monitoring risk.